Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy

Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy

ABSTRACT Background PD‐L1 expression in tumors and immune cells is a biomarker for the efficacy of anti‐PD‐1 antibody (APA) therapy across diverse cancers. Based on the results from the KEYNOTE‐048 trial, pembrolizumab monotherapy is indicated for platinum‐sensitive recurrent/metastatic head and nec...

Full description

Saved in:
Bibliographic Details
Main Authors: Akihiro Ohara, Taisuke Mori, Mai Itoyama, Kazuki Yokoyama, Shun Yamamoto, Ken Kato, Yoshitaka Honma
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Reports
Subjects:
biomarkers
chemotherapy
head and neck cancer
prognostic factor
Online Access:https://doi.org/10.1002/cnr2.70125
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items